The Effect of a Plant Sterols-Enriched Low-Fat Milk on Lipid Profile in Healthy Southern Chinese (COME-PASS) (COME-PASS)
The Effect of the Consumption of Low-Fat Milk Enriched With Plant Sterols on Serum Low-Density Lipoprotein Cholesterol in Healthy Southern Chinese (COME-PASS)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Southern Chinese male or female ≥ 18years.
- In good general health as evidenced by medical history
- Have the ability to understand the requirements of the study, provide written informed consent, including consent for the use and discloser of research-related health information, and comply with the study data collection procedures. Provide signed and dated informed consent form
Exclusion Criteria:
- Subject with familial hypercholesterolemia
- Ingestion of drugs known to interfere with lipid profiles, such as hormone replacement treatment, diuretics, beta-blockers, statin or other hypochoelsterolemic drug treatment
- Smoking > 10 cigarettes/day
- Subject with heavy alcohol intake (Alcohol > 3 glasses wine, or 2 beers, or 1 shot hard alcohol/day)
- Having milk intolerance or dislike
- Having major diseases such as diabetes (type I and type II), renal or liver diseases
- Subject presenting known allergy or hypersensitivity to milk proteins, soy and peanut
- Subject refusing to stop the consumption of plant sterols-enriched products if any during the study (other than the studied product)
- Subject receiving systemic treatment or topical treatment likely to interfere with evaluation of the study parameters
- Subject currently involved in a clinical trial or in an exclusion period following participation in another clinical trial
- Pregnancy or lactation
- Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Plant sterols-enriched low-fat milk
Daily consumption of 1.5g of plant sterols as provided by two servings of 273 ml of plant sterols-enriched low-fat milk for consecutive 3 weeks, each serving taken right before breakfast and lunch.
|
The study product is a dried partly skimmed milk powder with no more than 12% milk fat (11.4g total fat/100g product) containing unesterified, unhydrogenated plant sterols.
|
|
Placebo Comparator: Low-fat milk
Daily consumption of two servings of 273 ml of low-fat milk (without plant sterols) for consecutive 3 weeks, each serving taken right before breakfast and lunch.
|
The placebo product is a dried partly skimmed milk powder.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Mean of serum low-density lipoprotein cholesterol (LDL-C)
Time Frame: From baseline to week 3
|
From baseline to week 3
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change of serum LDL-C
Time Frame: From baseline to week 3
|
From baseline to week 3
|
|
Change of high-density lipoprotein cholesterol (HDL-C)
Time Frame: From baseline to week 3
|
From baseline to week 3
|
|
Change of total cholesterol
Time Frame: From baseline to week 3
|
From baseline to week 3
|
|
Change of triglycerides (TAG)
Time Frame: From baseline to week 3
|
From baseline to week 3
|
|
Change of serum creatinine
Time Frame: From baseline to week 3
|
From baseline to week 3
|
|
Changes of fasting blood glucose
Time Frame: From baseline to week 3
|
From baseline to week 3
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Cheung Bernard Man Yung, Li Ka Shing Faculty of Medicine, The University of Hong Kong
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CTC1430
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.